By targeting PKM splicing and favoring the expression of the PKM1 isoform, antisense oligonucleotide treatment effectively inhibits HCC dependence on aerobic glycolysis, leading to a reduction in HCC cell proliferation [221]. Here, PKM is linked to hepatocellular carcinoma.